TherapeuticsMD (TXMD) Misses Q1 EPS by 2c, Revenues Beat

TherapeuticsMD (NASDAQ: TXMD) reported Q1 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $11.3 million.

“I would like to thank our team for delivering a successful quarter during a challenging time. We have made significant progress across the business,” said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD. “We delivered a solid quarter in revenue. Recently, we extended the value of our lead asset, ANNOVERA, with the first Orange Book listed patent, and revised our strategic priorities and significantly reduced our operating cost structure, bringing us closer to achieving EBITDA break even in 2021.”

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules
• AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion
• Robinhood plans $2B convertible notes offering due 2029